Overview of intranasally delivered peptides: key considerations for pharmaceutical development

References

• Fosgerau K, Hoffmann T. Peptide therapeutics: current status and future directions. Drug Discov Today. 2015;20(1):122–128. .
   PubMed Web of Science ®Google Scholar
• Padhi A, Sengupta M, Sengupta S, et al. Antimicrobial peptides and proteins in mycobacterial therapy: current status and future prospects. Tuberculosis. 2014;94(4):363–373.
   PubMed Web of Science ®Google Scholar
• Giordano C, Marchiò M, Timofeeva E, et al. Neuroactive peptides as putative mediators of antiepileptic ketogenic diets. Front Neurol. 2014;5:63.
   Web of Science ®Google Scholar
• Research TM. Peptide therapeutics market - global industry analysis, size, share, growth, trends and forecast 2020: TMR. Transparency Market Res. 2017 September;12:2016.
   Google Scholar
• Lau JL, Dunn MK. Therapeutic peptides: historical perspectives, current development trends, and future directions. Biorg Med Chem. 2017;26(10):2700–2707.
   Web of Science ®Google Scholar
• Shaji J, Patole V. Protein and peptide drug delivery: oral approaches. Indian J Pharm Sci. 2008;70:269–277.
   Web of Science ®Google Scholar
• Escobar‐Chávez JJ, Bonilla‐Martínez D, Angélica M, et al. Microneedles: a valuable physical enhancer to increase transdermal drug delivery. J Clin Pharmacol. 2011;51(7):964–977.
   PubMed Web of Science ®Google Scholar
• Arora P, Sharma S, Garg S. Permeability issues in nasal drug delivery. Drug Discov Today. 2002;7(18):967–975.
   PubMed Web of Science ®Google Scholar
• Nyberg F. Neuropeptides in neuroprotection and neuroregeneration. Boca Raton: CRC Press; 2012.
   Google Scholar
• Illum L, Jordan FM, Lewis AL. Improvements in the absorption of therapeutic agents across mucosal membranes or the skin. Google Patents; 2011.
   Google Scholar
• Corbo DC, Huang YC, Chien YW. Nasal delivery of progestational steroids in ovariectomized rabbits. II. Effect of penetrant hydrophilicity. Int J Pharm. 1989;50(3):253–260.
   Google Scholar
• Gibson RE, Olanoff LS. Physicochemical determinants of nasal drug absorption. J Control Release. 1987;6(1):361–366.
   Google Scholar
• McMartin C, Hutchinson LE, Hyde R, et al. Analysis of structural requirements for the absorption of drugs and macromolecules from the nasal cavity. J Pharm Sci. 1987;76(7):535–540. .
   PubMed Web of Science ®Google Scholar
• Donovan MD, Flynn GL, Amidon GL. Absorption of polyethylene glycols 600 through 2000: the molecular weight dependence of gastrointestinal and nasal absorption. Pharm Res. 1990;7(8):863–868.
   PubMed Web of Science ®Google Scholar
• Donovan MD, Huang Y. Large molecule and particulate uptake in the nasal cavity: the effect of size on nasal absorption. Adv Drug Del Rev. 1998;29(1):147–155. .
   PubMed Web of Science ®Google Scholar
• Amodeo P, Motta A, Strazzullo G, et al. Conformational flexibility in calcitonin: the dynamic properties of human and salmon calcitonin in solution. J Biomol NMR. 1999;13(2):161–174.
   PubMed Web of Science ®Google Scholar
• Plosker GL, McTavish D. Intranasal salcatonin (Salmon Calcitonin). Drugs Aging. 1996;8(5):378–400.
   PubMedGoogle Scholar
• Laimou DK, Katsara M, Matsoukas M-TI, et al. Structural elucidation of Leuprolide and its analogues in solution: insight into their bioactive conformation. Amino Acids. 2010;39(5):1147–1160.
   PubMed Web of Science ®Google Scholar
• Pfizer Canada Inc., Quebec. Synarel (TM) [Product monograph]. 2015. [cited 2016 July 18]. Available from: http://www.pfizer.ca/sites/g/files/g10017036/f/201505/Synarel_PM_E_179947_26_February_2015.pdf
   Google Scholar
• Brogden RN, Buckley MM-T, Ward A. Buserelin. Drugs. 1990;39(3):399–437.
   PubMedGoogle Scholar
• Walse B, Kihlberg J, Drakenberg T. Conformation of desmopressin, an analogue of the peptide hormone vasopressin, in aqueous solution as determined by NMR spectroscopy. Eur J Biochem. 1998;252(3):428–440.
   PubMedGoogle Scholar
• Ferring Pharmaceuticals, New Zeland. Minirin nasal spray, [Product mongraph]. 2013. [cited 2016 Oct 21]. Available from: http://www.medsafe.govt.nz/profs/datasheet/m/Minirinnasalspray.pdf
   Google Scholar
• Vongvilai P, Isaka M, Kittakoop P, et al. Isolation and structure elucidation of enniatins L, M1, M2, and N: novel hydroxy analogs. Helv Chim Acta. 2004;87(8):2066–2073.
   Web of Science ®Google Scholar
• Liu D, Seuthe AB, Ehrler OT, et al. Oxytocin-receptor binding: why divalent metals are essential. J Am Chem Soc. 2005;127(7):2024–2025.
   PubMed Web of Science ®Google Scholar
• Morioka T, Loik ND, Hipolito CJ, et al. Selection-based discovery of macrocyclic peptides for the next generation therapeutics. Curr Opin Chem Biol. 2015;26:34–41.
   PubMed Web of Science ®Google Scholar
• Milewski M, Goodey A, Lee D, et al. Rapid absorption of dry-powder intranasal oxytocin. Pharm Res. 2016;33(8):1936-1944.
   PubMed Web of Science ®Google Scholar
• BioTopics. The 3-dimensional structure of glucagon, an alpha helix. [cited 2017 Feb 4]. Available from: http://www.biotopics.co.uk/jsmol/glucagon.html
   Google Scholar
• Pontiroli A, Calderara A, Perfetti M, et al. Pharmacokinetics of intranasal, intramuscular and intravenous glucagon in healthy subjects and diabetic patients. Eur J Clin Pharmacol. 1993;45(6):555–558.
   PubMed Web of Science ®Google Scholar
• Marx UC, Adermann K, Bayer P, et al. Solution structures of human parathyroid hormone fragments hPTH (1–34) and hPTH (1–39) and bovine parathyroid hormone fragment bPTH (1–37). Biochem Biophys Res Commun. 2000;267(1):213–220.
   PubMed Web of Science ®Google Scholar
• Macdonald B, Merutka GS. Intranasal formulations. Google Patents; 2012.
   Google Scholar
• Absorption similar for nasal, injected teriparatide: rheumatology news. [cited 2017 Mar 6]. Available from: http://www.mdedge.com/rheumatologynews/article/44136/osteoarthritis/absorption-similar-nasal-injected-teriparatide
   Google Scholar
• Gozes I, Morimoto BH, Tiong J, et al. NAP: research and development of a peptide derived from activity‐dependent neuroprotective protein (ADNP). CNS Drug Rev. 2005;11(4):353–368.
   PubMedGoogle Scholar
• Derewenda U, Derewenda Z, Dodson G, et al. Molecular structure of insulin: the insulin monomer and its assembly. Br Med Bull. 1989;45(1):4–18.
   PubMed Web of Science ®Google Scholar
• Leary AC, Dowling M, Cussen K, et al. Pharmacokinetics and pharmacodynamics of intranasal insulin spray (Nasulin™) administered to healthy male volunteers: influence of the nasal cycle. J Diabetes Sci Technol. 2008;2(6):1054–1060.
   PubMedGoogle Scholar
• Fisher A, Brown K, Davis S, et al. The effect of molecular size on the nasal absorption of water‐soluble compounds in the albino rat. J Pharm Pharmacol. 1987;39(5):357–362.
   PubMed Web of Science ®Google Scholar
• Hussain A, Hirai S, Bawarshi R. Nasal absorption of propranolol from different dosage forms by rats and dogs. J Pharm Sci. 1980;69(12):1411–1413.
   PubMed Web of Science ®Google Scholar
• Hussain AA, Kimura R, Huang CH. Nasal absorption of testosterone in rats. J Pharm Sci. 1984;73(9):1300–1301.
   PubMed Web of Science ®Google Scholar
• Morimoto BH, De Lannoy I, Fox AW, et al. Davunetide pharmacokinetics and distribution to brain after intravenous or intranasal administration to rat. Chim Oggi. 2009;27(2):16–20.
   Web of Science ®Google Scholar
• Morimoto BH. Early clinical development: case study of davunetide on translation from the bench to the clinic. Celerion Appl Transl Med. 2015. [cited 2016 Oct 25]. Available from: https://celerion.com/wordpress/wp-content/uploads/2015/04/Celerion_KSCPT-2015_Case-Study-of-Davunetide-on-Translation-from-Bench-to-Clinic.pdf
   Google Scholar
• Cremaschi D, Porta C, Ghirardelli R, et al. Endocytosis inhibitors abolish the active transport of polypeptides in the mucosa of the nasal upper concha of the rabbit. Biochim Biophys Acta Biomembr. 1996;1280(1):27–33.
   PubMed Web of Science ®Google Scholar
• Hersey S, Jackson R. Effect of bile salts on nasal permeability in vitro. J Pharm Sci. 1987;76(12):876–879.
   PubMed Web of Science ®Google Scholar
• Lochhead JJ, Thorne RG. Intranasal delivery of biologics to the central nervous system. Adv Drug Del Rev. 2012;64(7):614–628.
   PubMed Web of Science ®Google Scholar
• Mercer J, Helenius A. Virus entry by macropinocytosis. Nat Cell Biol. 2009;11(5):510–520.
   PubMed Web of Science ®Google Scholar
• Parton RG, Simons K. The multiple faces of caveolae. Nat Rev Mol Cell Biol. 2007;8(3):185–194.
   PubMed Web of Science ®Google Scholar
• Broadwell RD, Balin BJ. Endocytic and exocytic pathways of the neuronal secretory process and trans synaptic transfer of wheat germ agglutinin‐horseradish peroxidase in vivo. J Comp Neurol. 1985;242(4):632–650.
   PubMed Web of Science ®Google Scholar
• Balin BJ, Broadwell RD, Salcman M, et al. Avenues for entry of peripherally administered protein to the central nervous system in mouse, rat, and squirrel monkey. J Comp Neurol. 1986;251(2):260–280.
   PubMed Web of Science ®Google Scholar
• Hayashi M, Hirasawa T, Muroka T, et al. Comparison of water influx and sieving coefficient in rat jejunal, rectal and nasal absorptions of antipyrine. Chem Pharm Bull. 1985;33(5):2149–2152.
   PubMed Web of Science ®Google Scholar
• Madara JL, Dharmsathaphorn K. Occluding junction structure-function relationships in a cultured epithelial monolayer. J Cell Biol. 1985;101(6):2124–2133.
   PubMed Web of Science ®Google Scholar
• Korolkov VV, Allen S, Roberts CJ, et al. Study of NAP adsorption and assembly on the surface of HOPG. Peptides. 2014;62:55–58.
   PubMed Web of Science ®Google Scholar
• Shorten P, McMahon C, Soboleva T. Insulin transport within skeletal muscle transverse tubule networks. Biophys J. 2007;93(9):3001–3007.
   PubMed Web of Science ®Google Scholar
• Kabanov V, Skobeleva V, Rogacheva V, et al. Sorption of proteins by slightly cross-linked polyelectrolyte hydrogels: kinetics and mechanism. J Phys Chem B. 2004;108(4):1485–1490.
   Web of Science ®Google Scholar
• Wilkins DK, Grimshaw SB, Receveur V, et al. Hydrodynamic radii of native and denatured proteins measured by pulse field gradient NMR techniques. Biochemistry. 1999;38(50):16424–16431.
   PubMed Web of Science ®Google Scholar
• Inagaki M, Sakakura Y, Itoh H, et al. Macromolecular permeability of the tight junction of the human nasal mucosa. Rhinology. 1985;23(3):213.
   PubMedGoogle Scholar
• Claude P. Morphological factors influencing transepithelial permeability: A model for the resistance of thezonula occludens. J Membr Biol. 1978;39(2–3):219–232.
   PubMed Web of Science ®Google Scholar
• Lang SR, Staudenmann W, James P, et al. proteolysis of human calcitonin in excised bovine nasal mucosa: elucidation of the metabolic pathway by liquid secondary lonization mass spectrometry (lsims) and matrix assisted laser desorption lonization mass spectrometry (maldi). Pharm Res. 1996;13(11):1679–1685.
   PubMed Web of Science ®Google Scholar
• Morimoto K, Miyazaki M, Kakemi M. Effects of proteolytic enzyme inhibitors on nasal absorption of salmon calcitonin in rats. Int J Pharm. 1995;113(1):1–8.
   Google Scholar
• Lang S, Langguth P, Oschmann R, et al. Transport and metabolic pathway of thymocartin (TP4) in excised bovine nasal mucosa. J Pharm Pharmacol. 1996;48(11):1190–1196.
   PubMed Web of Science ®Google Scholar
• Chung FY, Donovan MD. Nasal pre-systemic metabolism of peptide drugs: substance P metabolism in the sheep nasal cavity. Int J Pharm. 1996;128(1):229–237.
   Google Scholar
• Beaven G, Gratzer W, Davies H. Formation and structure of gels and fibrils from glucagon. Eur J Biochem. 1969;11(1):37–42.
   PubMedGoogle Scholar
• Reno FE, Normand P, McInally K, et al. A novel nasal powder formulation of glucagon: toxicology studies in animal models. BMC Pharmacol Toxicol. 2015;16(1):29.
   PubMedGoogle Scholar
• Withdrawal of fusafungine-containing medicines from the market: Servier. [cited 2016 Oct 25]. Available from: http://www.servier.com/content/withdrawal-fusafungine-containing-medicines-market
   Google Scholar
• Lee WA, Ennis RD, Longenecker JP, et al. The bioavailability of intranasal salmon calcitonin in healthy volunteers with and without a permeation enhancer. Pharm Res. 1994;11(5):747–750.
   PubMed Web of Science ®Google Scholar
• Köhler M, Harris A. Pharmacokinetics and haematological effects of desmopressin. Eur J Clin Pharmacol. 1988;35(3):281–285.
   PubMed Web of Science ®Google Scholar
• Groot AN, Vree TB, Hekster YA, et al. Bioavailability and pharmacokinetics of sublingual oxytocin in male volunteers. J Pharm Pharmacol. 1995;47(7):571–575.
   PubMed Web of Science ®Google Scholar
• Sherr JL, Ruedy KJ, Foster NC, et al. Glucagon nasal powder: a promising alternative to intramuscular glucagon in youth with type 1 diabetes. Diabetes Care. 2016;39(4):555–562.
   PubMed Web of Science ®Google Scholar
• Macdonald B, Merutka GS Intranasal formulations. Google Patents; 2011.
   Google Scholar
• Di L. Strategic approaches to optimizing peptide ADME properties. AAPS J. 2015;17(1):134–143.
   PubMed Web of Science ®Google Scholar
• Bockus AT, McEwen CM, Lokey RS. Form and function in cyclic peptide natural products: a pharmacokinetic perspective. Curr Top Med Chem. 2013;13(7):821–836.
   PubMed Web of Science ®Google Scholar
• Roxin Á, Zheng G. Flexible or fixed: a comparative review of linear and cyclic cancer-targeting peptides. Future Med Chem. 2012;4(12):1601–1618.
   PubMed Web of Science ®Google Scholar
• Adessi C, Soto C. Converting a peptide into a drug: strategies to improve stability and bioavailability. Curr Med Chem. 2002;9(9):963–978.
   PubMed Web of Science ®Google Scholar
• Manning MC, Chou DK, Murphy BM, et al. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575.
   PubMed Web of Science ®Google Scholar
• DrugBank. Fusafungine. 2016. [cited 2017 Mar 2]. Available from: https://www.drugbank.ca/drugs/DB08965
   Google Scholar
• Proctor DF, Lundqvist G. Clearance of inhaled particles from the human nose. Arch Intern Med. 1973;131(1):132–139.
   PubMedGoogle Scholar
• Djupesland PG. Nasal drug delivery devices: characteristics and performance in a clinical perspective—a review. Drug Deliv Transl Res. 2013;3(1):42–62.
   PubMed Web of Science ®Google Scholar
• Tanaka A, Furubayashi T, Matsushita A, et al. Nasal absorption of macromolecules from powder formulations and effects of sodium carboxymethyl cellulose on their absorption. PLoS One. 2016;11(9):e0159150.
   PubMed Web of Science ®Google Scholar
• Ishikawa F, Katsura M, Tamai I, et al. Improved nasal bioavailability of elcatonin by insoluble powder formulation. Int J Pharm. 2001;224(1):105–114.
   PubMedGoogle Scholar
• Ishikawa F, Murano M, Hiraishi M, et al. Insoluble powder formulation as an effective nasal drug delivery system. Pharm Res. 2002;19(8):1097–1104.
   PubMed Web of Science ®Google Scholar
• Harris A, Nilsson I, Alkner U. Intranasal administration of peptides: nasal deposition, biological response, and absorption of desmopressin. J Pharm Sci. 1986;75(11):1085–1088.
   PubMed Web of Science ®Google Scholar
• Pringels E, Callens C, Vervaet C, et al. Influence of deposition and spray pattern of nasal powders on insulin bioavailability. Int J Pharm. 2006;310(1):1–7.
   PubMedGoogle Scholar
• Shimpi S, Chauhan B, Shimpi P. Cyclodextrins: application in different routes of drug administration. Acta Pharm. 2005;55(2):139–156.
   PubMedGoogle Scholar
• Merkus F, Verhoef J, Marttin E, et al. Cyclodextrins in nasal drug delivery. Adv Drug Del Rev. 1999;36(1):41–57.
   PubMed Web of Science ®Google Scholar
• Loftsson T, Brewster ME. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J Pharm Sci. 1996;85(10):1017–1025.
   PubMed Web of Science ®Google Scholar
• Hovgaard L, Brøndsted H. Drug delivery studies in Caco-2 monolayers. IV. Absorption enhancer effects of cyclodextrins. Pharm Res. 1995;12(9):1328–1332.
   PubMed Web of Science ®Google Scholar
• Irie T, Wakamatsu K, Arima H, et al. Enhancing effects of cyclodextrins on nasal absorption of insulin in rats. Int J Pharm. 1992;84(2):129–139.
   Google Scholar
• Corbo DC, Liu JC, Chienx YW. Characterization of the barrier properties of mucosal membranes. J Pharm Sci. 1990;79(3):202–206.
   PubMed Web of Science ®Google Scholar
• Marttin E, Verhoef JC, Cullander C, et al. Confocal laser scanning microscopic visualization of the transport of dextrans after nasal administration to rats: effects of absorption enhancers. Pharm Res. 1997;14(5):631–637.
   PubMed Web of Science ®Google Scholar
• Merkus FW, Verhoef JC, Romeijn SG, et al. Absorption enhancing effect of cyclodextrins on intranasally administered insulin in rats. Pharm Res. 1991;8(5):588–592.
   PubMed Web of Science ®Google Scholar
• Leonard AK, Sestak JO, Costantino HR, et al. Intranasal carbetocin formulations and methods for the treatment of autism. Google Patents; 2008.
   Google Scholar
• Rouse SL, Marcoux J, Robinson CV, et al. Dodecyl maltoside protects membrane proteins in vacuo. Biophys J. 2013;105(3):648–656.
   PubMed Web of Science ®Google Scholar
• Ellinger P, Kluth M, Stindt J, et al. Detergent screening and purification of the human liver ABC transporters BSEP (ABCB11) and MDR3 (ABCB4) expressed in the yeast Pichia pastoris. PLoS One. 2013;8(4):e60620.
   PubMed Web of Science ®Google Scholar
• Maggio ET. Intravail™: highly effective intranasal delivery of peptide and protein drugs. Expert Opin Drug Deliv. 2006;3(4):529–539.
   PubMedGoogle Scholar
• Uchiyama T, Sugiyama T, Quan YS, et al. Enhanced permeability of insulin across the rat intestinal membrane by various absorption enhancers: their intestinal mucosal toxicity and absorption‐enhancing mechanism of n‐Lauryl‐β‐D‐maltopyranoside. J Pharm Pharmacol. 1999;51(11):1241–1250.
   PubMed Web of Science ®Google Scholar
• Chen S, Eiting K, Li A, et al. Peptide drug permeation enhancement by select classes of lipids. 45th American Society for Cell Biology Meeting; 2005 Dec 10–14; San Francisco: Nastech Pharmaceutical Company Inc., University of Washington.
   Google Scholar
• Micelles: virtual Chembook. [cited 2017 April 5]. Available from: http://chemistry.elmhurst.edu/vchembook/558micelle.html
   Google Scholar
• Liu DZ, Lecluyse EL, Thakker DR. Dodecylphosphocholine‐mediated enhancement of paracellular permeability and cytotoxicity in Caco‐2 cell monolayers. J Pharm Sci. 1999;88(11):1161–1168.
   PubMed Web of Science ®Google Scholar
• Bösch C, Brown LR, Wüthrich K. Physicochemical characterization of glucagon-containing lipid micelles. Biochim Biophys Acta Biomembr. 1980;603(2):298–312.
   PubMedGoogle Scholar
• Kaarsholm NC Stabilized aqueous peptide solutions. Google Patents; 2002.
   Google Scholar
• Sinswat P, Tengamnuay P. Enhancing effect of chitosan on nasal absorption of salmon calcitonin in rats: comparison with hydroxypropyl-and dimethyl-β-cyclodextrins. Int J Pharm. 2003;257(1):15–22.
   PubMedGoogle Scholar
• Ahsan F, Arnold J, Meezan E, et al. Enhanced bioavailability of calcitonin formulated with alkylglycosides following nasal and ocular administration in rats. Pharm Res. 2001;18(12):1742–1746.
   PubMed Web of Science ®Google Scholar
• Maggio ET, Meezan E, Ghambeer DKS, et al. Highly bioavailable nasal calcitonin - potential for expanded use in analgesia. Drug Deliv Technol. 2010;10(1):20.
   Google Scholar
• Illum L, Farraj NF, Davis SS. Chitosan as a novel nasal delivery system for peptide drugs. Pharm Res. 1994;11(8):1186–1189.
   PubMed Web of Science ®Google Scholar
• Chaturvedi M, Kumar M, Pathak K. A review on mucoadhesive polymer used in nasal drug delivery system. J Adv Pharm Technol Res. 2011;2(4):215.
   PubMedGoogle Scholar
• Watts P, Smith A. PecSys: in situ gelling system for optimised nasal drug delivery. Expert Opin Drug Deliv. 2009;6(5):543–552.
   PubMed Web of Science ®Google Scholar
• Axelos MAV, Thibault JF. The chemistry of low-methoxyl pectin gelation. In: Reginald H. Walter, editor, The chemistry and technology of pectin. Cambridge: Academic Press; 1991. p. 109-118
   Google Scholar
• Science 2.0. Nose-to-Brain Research Of Oxytocin In Autism Spectrum Disorders. [ cited 2016 Oct 21]. Available from: https://www.science20.com/news_articles/nosetobrain_research_oxytocin_autism_spectrum_disorders-96209.
   Google Scholar
• Tsuneji N, Yuji N, Naoki N, et al. Powder dosage form of insulin for nasal administration. J Control Release. 1984;1(1):15–22.
   Google Scholar
• Oechslein CR, Fricker G, Kissel T. Nasal delivery of octreotide: absorption enhancement by particulate carrier systems. Int J Pharm. 1996;139(1):25–32.
   Google Scholar
• Lansley AB, Sanderson MJ, Dirksen ER. Control of the beat cycle of respiratory tract cilia by Ca2+ and cAMP. Am J PhysiolLung Cell Mol Physiol. 1992;263(2):L232–L42.
   PubMedGoogle Scholar
• Suzuki Y, Makino Y. Mucosal drug delivery using cellulose derivatives as a functional polymer. J Control Release. 1999;62(1):101–107.
   PubMed Web of Science ®Google Scholar
• De Fraissinette A, Kolopp M, Schiller I, et al. In vitro tolerability of human nasal mucosa: histopathological and scanning electron-microscopic evaluation of nasal forms containing Sandostatin®. Cell Biol Toxicol. 1995;11(5):295–301.
   PubMed Web of Science ®Google Scholar
• Shahiwala A, Misra A. Nasal delivery of levonorgestrel for contraception: an experimental study in rats. Fertil Steril. 2004;81:893–898.
   PubMed Web of Science ®Google Scholar
• Borchard G, Lueβen HL, de Boer AG, et al. The potential of mucoadhesive polymers in enhancing intestinal peptide drug absorption. III: effects of chitosan-glutamate and carbomer on epithelial tight junctions in vitro. J Control Release. 1996;39(2):131–138.
   Web of Science ®Google Scholar
• Sakr FM. Nasal administration of glucagon combined with dimethyl-β-cyclodextrin: comparison of pharmacokinetics and pharmacodynamics of spray and powder formulations. Int J Pharm. 1996;132(1):189–194.
   Google Scholar
• Mrsny RJ, Daugherty A. Proteins and peptides: pharmacokinetic, pharmacodynamic, and metabolic outcomes. Boca Raton: CRC Press; 2009.
   Google Scholar
• Oh D-M, Sinko PJ, Amidon GL. Predicting oral drug absorption in human. In: David Z. D Argenio, editor, A macroscopic mass balance approach for passive and carrier-mediated compounds. Advanced methods of pharmacokinetic and pharmacodynamic systems analysis. New York City: Springer; 1991. p. 3–11.
   Google Scholar
• Proctor DF, Andersen IHP. The nose, upper airway physiology and the atmospheric environment. Amsterdam, New York City: Elsevier Biomedical Press; 1982.
   Google Scholar
• GenScript. Salmon calcitonin. [cited 2017 Mar 2]. Available from: http://www.genscript.com/peptide/RP11099-Calcitonin_salmon.html
   Google Scholar
• Vickery B, Benjamin E, Fu CC, et al. Intranasal administration of polypeptides in powdered form. Google Patents; 2005.
   Google Scholar
• Sanofi-aventis Canada. Superfact Buserelin acetate: Sanofi-Aventis Canada, Inc.. 2015. [cited 2017 Mar 2]. Available from: http://products.sanofi.ca/en/suprefact.pdf
   Google Scholar
• United States pharmacopeia. USP36 NF31, 2013: U. S. Pharmacopoeia National Formulary. Desmopressin acetate. Rockville: United States pharmacopeia. 2012. p. 2185.
   Google Scholar
• Jacques S. Process for preparation of fusafungine. Google Patents; 1968.
   Google Scholar
• Information NCfB. PubChem Compound Database; CID=439302. [cited 2017 Mar 2]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/oxytocin#section=Top
   Google Scholar
• Lilly USA. Glucagon for injection. 1999. [ cited 2017 Mar 2]. Available from: http://pi.lilly.com/us/rglucagon-pi.pdf
   Google Scholar
• Innovagen. NAP. [cited 2017 Mar 2].  Available from: http://shop.innovagen.com/peptide.php?NAP&code=SP-5337
   Google Scholar
• Fischel-Ghodsian F, Brown L, Mathiowitz E, et al. Enzymatically controlled drug delivery. Proc Natl Acad Sci. 1988;85(7):2403–2406.
   PubMed Web of Science ®Google Scholar
• Pujara CP, Shao Z, Duncan MR, et al. Effects of formulation variables on nasal epithelial cell integrity: biochemical evaluations. Int J Pharm. 1995;114(2):197–203.
   Google Scholar